β-blocker adherence among patients with congenital Long QT Syndrome: a nationwide study.
Johanna KrøllJawad Haider ButtHenrik Kjaerulf JensenEmil Loldrup FosboelCamilla H B JespersenBo G WinkelJørgen K KantersGunnar H GislasonChristian Torp-PedersenLars KøberHenning BundgaardJacob Tfelt HansenPeter E WeekePublished in: European heart journal. Quality of care & clinical outcomes (2022)
Reduced β-blocker adherence was common with more than a third of patients having a treatment break >60 days after cLQTS diagnosis. Patients with psychiatric disease, self-reported β-blocker side-effects, and ICD were more likely to display reduced adherence whereas a severe cLQTS disease manifestation was associated with optimal β-blocker adherence.